Lv3
350 积分 2025-03-19 加入
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
6小时前
待确认
Adoptive Cell Therapy for Nonhematologic Solid Tumors
1天前
已完结
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
1个月前
已关闭
Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL
1个月前
已关闭
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial
1个月前
已完结
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
2个月前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
2个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
2个月前
已完结
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
2个月前
已关闭
皖公网安备34019202002308
